Therefore, developing non-cardiotoxic selective COX-2 inhibitors and/or agents that target the enzymes regulating PGE2 synthesis and degradation may lead to valuable chemopreventive or -therapeutic approaches for patients with mutant KRAS lung cancer. Here, PTGS2 is linked to lung carcinoma.